muscarinic agents
Recently Published Documents


TOTAL DOCUMENTS

58
(FIVE YEARS 2)

H-INDEX

14
(FIVE YEARS 0)

2021 ◽  
Vol 2021 (3) ◽  
Author(s):  
Nigel J. M. Birdsall ◽  
Sophie Bradley ◽  
David A. Brown ◽  
Noel J. Buckley ◽  
R.A. John Challiss ◽  
...  

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates.



2021 ◽  
Vol 2021 (2) ◽  
Author(s):  
Nigel J. M. Birdsall ◽  
Sophie Bradley ◽  
David A. Brown ◽  
Noel J. Buckley ◽  
R.A. John Challiss ◽  
...  

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates. I





2017 ◽  
Vol 129 (5) ◽  
pp. 500-512 ◽  
Author(s):  
Nicola A Hanania ◽  
Suzanne C. Lareau ◽  
Barbara P. Yawn


Eye ◽  
2016 ◽  
Vol 30 (7) ◽  
pp. 925-928 ◽  
Author(s):  
V Öner ◽  
A Bulut ◽  
K Öter


2013 ◽  
Vol 33 (3) ◽  
pp. 245-256 ◽  
Author(s):  
Debora L Nickla ◽  
Xiaoying Zhu ◽  
Josh Wallman
Keyword(s):  




Sign in / Sign up

Export Citation Format

Share Document